logo
Equinor ASA: Announcement of cash dividend per share in NOK for fourth quarter 2024

Equinor ASA: Announcement of cash dividend per share in NOK for fourth quarter 2024

Equinor ASA (OSE: EQNR, NYSE: EQNR) announced on 5 February 2025 a cash dividend per share of USD 0.37 for fourth quarter 2024.
The NOK cash dividend per share is based on average USDNOK fixing rate from Norges Bank in the period plus/minus three business days from record date 16 May 2025, in total seven business days.
Average Norges Bank fixing rate for this period was 10.3284. Total cash dividend for fourth quarter 2024 of is consequently NOK 3.8215 per share.
On 28 May 2025, the cash dividend will be paid to relevant shareholders on Oslo Børs (Oslo Stock Exchange) and to holders of American Depositary Receipts ('ADRs') on New York Stock Exchange.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Certain DWS Closed-End Funds Announce Extension of Share Repurchases and The Central and Eastern Europe Fund, Inc. Announces Extension of Minimum Period for Partial Advisory Fee Waiver
Certain DWS Closed-End Funds Announce Extension of Share Repurchases and The Central and Eastern Europe Fund, Inc. Announces Extension of Minimum Period for Partial Advisory Fee Waiver

Business Wire

timean hour ago

  • Business Wire

Certain DWS Closed-End Funds Announce Extension of Share Repurchases and The Central and Eastern Europe Fund, Inc. Announces Extension of Minimum Period for Partial Advisory Fee Waiver

NEW YORK--(BUSINESS WIRE)--The Central and Eastern Europe Fund, Inc. (NYSE: CEE), The European Equity Fund, Inc. (NYSE: EEA), and The New Germany Fund, Inc. (NYSE: GF) (each, a 'Fund,' and collectively, the 'Funds') each announced today that its Board of Directors has approved an extension of the current repurchase authorization permitting open market share repurchases for an additional twelve-month period. Each Fund may continue to purchase outstanding shares of its common stock in open-market transactions over the twelve-month period from August 1, 2025 through July 31, 2026 when the Fund's shares trade at a discount to net asset value ('NAV') and such purchases are deemed to be in the best interests of the Fund. The amount and timing of the repurchases will be at the discretion of DWS Investment Management Americas, Inc., the Funds' administrator, and subject to market conditions and investment considerations. Any purchases will be made at prices that will be accretive to each Fund's NAV. The authorization of the extension of the Funds' repurchase programs follows the current repurchase programs, which commenced on August 1, 2024 and continue through July 31, 2025. Results of repurchases under each Fund's program appear in the Fund's shareholder reports. In addition, each Fund announced that its Board continues to reserve its discretion to determine if it would be appropriate to initiate a tender offer during the twelve-month period from August 1, 2025 through July 31, 2026. Each Board intends to continue to consider this matter on a regular basis. In addition, CEE announced today that the Fund's investment advisor, DWS International GmbH, has voluntarily agreed to continue to waive 50% of its advisory fee until further notice but at least until December 31, 2025. Previously, such partial fee waiver was to continue until further notice but at least through September 30, 2025. Important Information Closed-end funds, unlike open-end funds, are not continuously offered. There is a one-time public offering and once issued, shares of closed-end funds are sold in the open market through a stock exchange. Shares of closed-end funds frequently trade at a discount to net asset value. The price of the fund's shares is determined by a number of factors, several of which are beyond the control of the fund. Therefore, the fund cannot predict whether its shares will trade at, below or above net asset value. The Central and Eastern Europe Fund, Inc. is non-diversified and can take larger positions in fewer issues, increasing its potential risk. Investing in foreign securities presents certain risks, such as currency fluctuations, political and economic changes, and market risks. Emerging markets tend to be more volatile and less liquid than the markets of more mature economies, and generally have less diverse and less mature economic structures and less stable political systems than those of developed countries. Any fund that focuses in a particular segment of the market or region of the world will generally be more volatile than a fund that invests more broadly. This fund is non-diversified and can take larger positions in fewer issues, increasing its potential risk. The European Equity Fund, Inc. is diversified and primarily focuses its investments in equity securities of issuers domiciled in Europe, thereby increasing its vulnerability to developments in that region. The New Germany Fund, Inc. is diversified and primarily focuses its investments in Germany, thereby increasing its vulnerability to developments in that country. Investing in foreign securities, particularly of emerging markets, presents certain risks, such as currency fluctuations, and risks of currency and capital controls, political and economic changes, and market risks. Any fund that concentrates in a particular segment of the market or a particular geographical region will generally be more volatile than a fund that invests more broadly. War, terrorism, sanctions, economic uncertainty, trade disputes, public health crises and related geopolitical events have led, and, in the future, may lead to significant disruptions in US and world economies and markets, which may lead to increased market volatility and may have significant adverse effects on the Funds and their investments. The European Union, the United States and other countries have imposed sanctions on Russia in response to Russian military and other actions in recent years. These sanctions have adversely affected Russian individuals, issuers and the Russian economy. Russia, in turn, has imposed sanctions targeting Western individuals, businesses and products. The various sanctions have adversely affected, and may continue to adversely affect, not only the Russian economy, but also the economies of many countries in Europe, including countries in Central and Eastern Europe. In the case of the Central and Eastern Europe Fund, Inc., Russia's invasion of Ukraine has materially adversely affected, and may continue to materially adversely affect, the value and liquidity of the Fund's portfolio. This press release shall not constitute an offer to sell or a solicitation to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer or solicitation or sale would be unlawful prior to registration or qualification under the laws of such state or jurisdiction. Certain statements contained in this release may be forward-looking in nature. These include all statements relating to plans, expectations, and other statements that are not historical facts and typically use words like 'expect,' 'anticipate,' 'believe,' 'intend,' and similar expressions. Such statements represent management's current beliefs, based upon information available at the time the statements are made, with regard to the matters addressed. All forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those expressed in, or implied by, such statements. Management does not undertake any obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise. The following factors, among others, could cause actual results to differ materially from forward-looking statements: (i) the effects of adverse changes in market and economic conditions; (ii) legal and regulatory developments; and (iii) other additional risks and uncertainties, including public health crises (including the recent pandemic spread of the novel coronavirus), war, terrorism, trade disputes and related geopolitical events. Past performance is no guarantee of future results. NOT FDIC/ NCUA INSURED • MAY LOSE VALUE • NO BANK GUARANTEE NOT A DEPOSIT • NOT INSURED BY ANY FEDERAL GOVERNMENT AGENCY DWS Distributors, Inc. 222 South Riverside Plaza Chicago, IL 60606-5808 Tel (800) 621-1148 © 2025 DWS Group GmbH & Co. KGaA. All rights reserved The brand DWS represents DWS Group GmbH & Co. KGaA and any of its subsidiaries such as DWS Distributors, Inc. which offers investment products or DWS Investment Management Americas, Inc. and RREEF America L.L.C. which offer advisory services. (R-106684-1) (07/25)

Why Gorman-Rupp (GRC) Stock Is Up Today
Why Gorman-Rupp (GRC) Stock Is Up Today

Yahoo

timean hour ago

  • Yahoo

Why Gorman-Rupp (GRC) Stock Is Up Today

What Happened? Shares of gorman-Rupp (NYSE:GRC) manufactures and sells pumps globally. jumped 7.6% in the afternoon session after the company reported record second-quarter financial results that surpassed analyst expectations, driven by strong sales linked to infrastructure spending. The industrial pump manufacturer posted earnings of $0.60 per share on a record $179 million in revenue, surpassing analyst expectations. This performance marked a significant improvement compared to the $0.32 per share reported in the same quarter last year. The revenue growth was primarily fueled by a $3.5 million increase in sales to the municipal market, which the company attributed to infrastructure investment. The fire suppression, industrial, and petroleum markets also contributed to the gains. In a further sign of strength, Gorman-Rupp announced record incoming orders of $188 million, up 15.7% from the prior year, which suggested a positive outlook for the second half of the year. Is now the time to buy Gorman-Rupp? Access our full analysis report here, it's free. What Is The Market Telling Us Gorman-Rupp's shares are not very volatile and have only had 5 moves greater than 5% over the last year. In that context, today's move indicates the market considers this news meaningful, although it might not be something that would fundamentally change its perception of the business. The biggest move we wrote about over the last year was 4 months ago when the stock dropped 5.1% after stocks gave back some of the gains from the previous day as the White House clarified the tariffs on imports from China would add up to 145%, while the baseline 10% tariffs remained in place for all countries. This reminded markets that the global trade environment remained volatile, limiting the potential for sustained gains. Also, President Trump said he was willing to accept pain in the short term, and was aware his policies could cause a recession, but he remained more mindful of a more severe case of economic depression (higher unemployment and prolonged downturn). For investors, this suggested that the administration could prioritize long-term structural shifts over near-term economic stability, further increasing policy-driven risk in the markets. Gorman-Rupp is up 11.2% since the beginning of the year, and at $41.46 per share, it is trading close to its 52-week high of $43.09 from November 2024. Investors who bought $1,000 worth of Gorman-Rupp's shares 5 years ago would now be looking at an investment worth $1,295. Here at StockStory, we certainly understand the potential of thematic investing. Diverse winners from Microsoft (MSFT) to Alphabet (GOOG), Coca-Cola (KO) to Monster Beverage (MNST) could all have been identified as promising growth stories with a megatrend driving the growth. So, in that spirit, we've identified a relatively under-the-radar profitable growth stock benefiting from the rise of AI, available to you FREE via this link. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Why Centene (CNC) Stock Is Trading Up Today
Why Centene (CNC) Stock Is Trading Up Today

Yahoo

timean hour ago

  • Yahoo

Why Centene (CNC) Stock Is Trading Up Today

What Happened? Shares of health coverage company Centene (NYSE:CNC) jumped 5.9% in the afternoon session after the company reported second-quarter results that missed earnings estimates, but the stock rallied as investors looked past the disappointment as sales came in ahead of expectations. Centene posted its first quarterly earnings miss in four years, swinging to an adjusted loss per share of $0.16, a stark contrast to the profit recorded in the same quarter last year. The company also set its 2025 earnings guidance significantly below analyst expectations, citing worse-than-expected cost trends in its Affordable Care Act (ACA) Marketplace business. Despite the profitability issues, total revenues for the quarter came in strong at $48.7 billion, handily beating expectations. While the stock initially dropped sharply in pre-market trading on the earnings miss, it reversed course and rallied during the company's earnings call. This turnaround suggested investors may have gained confidence from management's commentary and their stated plan to address the cost issues and restore profitability. Is now the time to buy Centene? Access our full analysis report here, it's free. What Is The Market Telling Us Centene's shares are somewhat volatile and have had 13 moves greater than 5% over the last year. In that context, today's move indicates the market considers this news meaningful but not something that would fundamentally change its perception of the business. The previous big move we wrote about was 7 days ago when the stock dropped 3.9% as several negative developments weighed on the sector. Weakness in managed care providers was a significant factor, with companies like Elevance Health and Humana seeing declines due to an analyst downgrade and a lost lawsuit regarding Medicare bonus payments, respectively. Additionally, some pharmaceutical and biotech companies experienced sharp drops following unfavorable news; for instance, Sarepta Therapeutics plunged after a report indicated another patient death tied to its experimental gene therapy, and GSK's blood cancer drug dosage was voted against by the FDA advisory committee. Broader market sentiment, including concerns about rising costs and inadequate pricing for 2025 plans among health insurers, also contributed to the downward pressure on healthcare equities. Centene is down 53.3% since the beginning of the year, and at $28.29 per share, it is trading 64.7% below its 52-week high of $80.23 from September 2024. Investors who bought $1,000 worth of Centene's shares 5 years ago would now be looking at an investment worth $420.47. Here at StockStory, we certainly understand the potential of thematic investing. Diverse winners from Microsoft (MSFT) to Alphabet (GOOG), Coca-Cola (KO) to Monster Beverage (MNST) could all have been identified as promising growth stories with a megatrend driving the growth. So, in that spirit, we've identified a relatively under-the-radar profitable growth stock benefiting from the rise of AI, available to you FREE via this link.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store